Get the Stockscreener App
159.83
1.36%
2.14
Biogen Inc Stock (BIIB) Latest News
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea - PR Newswire
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
January 2025 Options Now Available For Biogen (BIIB) - Nasdaq
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? - Insider Monkey
Clark Estates Inc. NY Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Smart Money Is Betting Big In BIIB Options - Benzinga
Eisai and Biogen Japan collaborate to lead dementia genomics R&D with NCNP in Japan - BSA bureau
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over - The Motley Fool
Daiwa Securities Group Inc. Raises Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Swedbank AB Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan - japancorp.net
Biogen: Jefferies confirms its target as it awaits Ocrevus - Marketscreener.com
Bedell Frazier Investment Counselling LLC Buys 17,628 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Antisense & RNAi Therapeutics Market May See a Big Move | Isarna - openPR
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink? - MSN
Are Wall Street Analysts Predicting Biogen Stock Will Climb Or Sink? - Barchart
Charles Schwab Investment Management Inc. Boosts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Boosted by Massachusetts Financial Services Co. MA - MarketBeat
Notable analyst calls this week: Roku, Nvidia and Biogen among top picks - MSN
Notable analyst calls this week: Roku, Nvidia and Biogen among top picks (NASDAQ:ROKU) - Seeking Alpha
B. Metzler seel. Sohn & Co. Holding AG Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Natixis Advisors LLC Sells 10,054 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock - Insider Monkey
BIIB (Biogen) 3-Year FCF Growth Rate : -28.10% (As of Sep. 2024) - GuruFocus.com
Biogen price target lowered to $207 from $251 at Mizuho - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Mutual of America Capital Management LLC Has $4.03 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Monoclonal Antibody Therapeutics Market Is Booming Worldwide - openPR
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at Mizuho - MarketBeat
Primecap Management Co. CA Sells 23,215 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals
BIIB (Biogen) Predictability Rank - GuruFocus.com
Biogen (WBO:BIIB) Profitability Rank : 7 (As of Sep. 2024) - GuruFocus.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - AOL
Biogen Unusual Options Activity For November 20 - Benzinga
ANCA Vasculitis Pipeline Trends 2024: Clinical Trials, - openPR
Biogen ‘welcomes’ EC decision to revoke CMAs for generic versions of Tecfidera - MSN
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
(BIIB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
European committee takes a second look at Alzheimer's drug and now says it should be approved - MSN
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Biogen at the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - MSN
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III - BioSpace
Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation - PMLiVE
Thrivent Financial for Lutherans Has $36.57 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UCB: positive phase 3 results in lupus - Marketscreener.com
Empowered Funds LLC Acquires 15,506 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen: positive phase 3 results in lupus - Marketscreener.com
BIIBBiogen Inc. Latest Stock News & Market Updates - StockTitan
Biogen/UCB’s Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time - Citeline
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - Biogen | Investor Relations
Dapirolizumab Pegol Phase 3 Data Presented at the American - GlobeNewswire
Biogen's Lupus Drug Shows 49.5% Response Rate in Phase 3 Trial, Beats Standard Care | BIIB Stock News - StockTitan
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Yahoo Finance
Needham downgrades Biogen on slow growth of Alzheimer's drug By Investing.com - Investing.com Canada
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales (NASDAQ:BIIB) - Seeking Alpha
Needham downgrades Biogen on slow growth of Alzheimer's drug - Investing.com
Opuviz is latest EC-approved ophthalmology biosimilar - The Pharma Letter
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):